Treatment for cardiac amyloidosis looks very different depending on which type you have — ATTR or AL — and also different from typical heart failure treatment, since standard medications aren't always safe or effective here. This page walks through the main medication categories used for each type, and explains why some familiar heart failure medications are used differently, or avoided altogether, in amyloidosis. (For background on the disease itself, see Cardiac Amyloidosis.)
Why Amyloidosis Needs a Different Approach
Most standard heart failure medications were studied in HFrEF (heart failure with reduced ejection fraction — in plain terms, a heart with weak contraction), where the problem is a weak pump that benefits from medications that reduce strain on it. Cardiac amyloidosis is different: the heart muscle is stiff and restrictive, with a pumping volume that's often already fixed and limited, and blood pressure that's frequently low to begin with. Medications that lower blood pressure or heart rate further — the backbone of standard heart failure treatment — can leave patients with amyloidosis feeling worse, not better. This is why treatment is built around the specific type of amyloid, not a one-size-fits-all heart failure protocol.
ATTR Amyloidosis: TTR Stabilizers
- Tafamidis (brand names Vyndaqel, Vyndamax) — the first medication proven to slow ATTR cardiac amyloidosis; it binds to the transthyretin (TTR) protein in the blood and stabilizes it, preventing it from breaking apart and misfolding into amyloid deposits. Large trials showed it reduces hospitalizations and improves survival in ATTR cardiac amyloidosis
- Acoramidis (brand name Attruby) — a newer TTR stabilizer, also shown to slow disease progression, offering another option in this class
- These medications don't reverse amyloid that has already deposited — they slow further buildup, which is why starting treatment as early as possible in the disease course matters
ATTR Amyloidosis: TTR Gene-Silencing Therapies
- Patisiran and vutrisiran (brand names Onpattro and Amvuttra) work differently from stabilizers — they reduce the amount of TTR protein the body produces in the first place, using gene-silencing technology, meaning there's simply less TTR available to misfold and deposit
- These medications were originally developed and approved for the nerve damage (polyneuropathy) caused by hereditary ATTR, and are increasingly used or studied specifically for the cardiac form of the disease as well — ask your care team whether one of these fits your specific situation
- They're given by injection or infusion on a periodic schedule rather than as a daily pill
AL Amyloidosis: Hematology-Led Treatment
AL amyloidosis is fundamentally a blood/bone marrow disease, so treatment is led by hematology/oncology rather than cardiology, using approaches similar to those for multiple myeloma:
- Bortezomib-based regimens — a proteasome inhibitor, often combined with other agents, aimed at reducing the abnormal plasma cells producing the toxic light-chain proteins
- Daratumumab — an antibody-based therapy targeting a marker (CD38) on the abnormal plasma cells, increasingly used as part of initial AL treatment
- Cyclophosphamide and dexamethasone — commonly combined with the above as part of a multi-drug regimen
- Autologous stem cell transplant — considered in eligible patients as part of more intensive treatment, aiming for a deeper and more durable response
- Because AL amyloidosis can progress quickly and affect multiple organs, treatment usually starts urgently once diagnosed, and your cardiology and hematology teams will coordinate closely
Medications Often Avoided or Used With Caution
- Digoxin — generally avoided or used with extra caution, since it can bind to amyloid fibrils in a way that raises the risk of dangerous heart rhythm problems, even at doses that would be safe in other patients (see Digoxin)
- Standard "four pillar" HFrEF medications (see Heart Failure Medications: The Four Pillars) — beta-blockers, ACE inhibitors/ARBs/ARNI, and MRAs are often poorly tolerated, since they can further lower an already-limited blood pressure and worsen fatigue; your team may use lower doses, skip certain classes, or take a different approach entirely
- Calcium channel blockers — classically avoided in amyloidosis, for similar reasons: they can worsen the heart's pumping ability and blood pressure in this specific condition
Medications That Still Play a Role
- Diuretics remain the mainstay for managing fluid retention and swelling in both ATTR and AL amyloidosis, and are generally well tolerated (see Diuretics)
- Anticoagulants are often considered even without a formal diagnosis of atrial fibrillation, since amyloid-infiltrated atria may not contract effectively even when the heart rhythm looks normal on monitoring, raising the risk of blood clots (see Anticoagulants)
- Pacemakers aren't a medication, but are sometimes needed if amyloid deposits disrupt the heart's electrical system, independent of medication treatment
Common Questions
Can these medications cure amyloidosis?
ATTR stabilizers and gene-silencing therapies slow progression rather than reverse existing damage, so earlier treatment generally means more heart function preserved. AL amyloidosis treatment aims for a deep hematologic response, which can significantly improve organ function and survival, though outcomes depend on how early treatment starts and how the disease responds.
Why was I told to avoid a medication I've taken before for other heart problems?
Amyloidosis changes how the heart tolerates certain medications — something that was safe or even standard treatment for a different heart condition can be poorly tolerated or unsafe once amyloidosis is diagnosed.
Are the ATTR medications available as pills?
Tafamidis and acoramidis are both taken by mouth; patisiran and vutrisiran are given by injection or infusion on a periodic schedule.
Will I need both a cardiologist and a hematologist?
Only if you have AL amyloidosis — ATTR amyloidosis is generally managed by cardiology (sometimes with neurology involved for hereditary ATTR with neuropathy), while AL amyloidosis requires hematology/oncology working alongside cardiology.
How long will I need to stay on these medications?
Generally indefinitely for ATTR stabilizers and gene-silencing therapies, since they work by ongoing suppression or stabilization rather than a cure. AL amyloidosis treatment duration depends on your hematologic response and is determined by your hematology team.